The topic of today's article will revolve around a Liraglutide peptide and some brief research on its potential mechanism of action. If this topic interests you, keep reading to learn more. All the information you need will be presented down below.
Liraglutide composes 30 to 31 amino acids. Because of its structural similarity to GLP-1, scientists consider this to be a lipopeptide. It consists of the amino acid arginine and a hexadecanoyl group, which is thought to be responsible for the compound's alleged potential to have a prolonged impact. [i]
The researchers hypothesize that Liraglutide may imitate the activity of the hormone GLP-1, which is generated in the intestines. GLP-1 may boost insulin production and slow the stomach's emptying rate following ingestion. The satiety area in the brain may also be activated by Liraglutide, which results in the subject feeling full, as speculated by researchers. Additionally, scientists hypothesize it may have the potential to stimulate insulin secretion from beta cells in the pancreas, which decreases the amount of glucose in the blood.
Overview
Studies suggest Liraglutide, thought to be very similar to GLP-1, may potentially generate what is known in the scientific community as the "incretin effect," which is a term that Dr. Holst created. [ii] Incretins are metabolic hormones secreted in the gastrointestinal system. It is believed that incretins bring about a decrease in the amount of sugar that is found in the blood. In addition, GLP-1 agonistic receptors are situated on the surface of beta cells that can be found in the pancreas. Because of this, it is speculated that GLP-1 may likely bind to this receptor, which may cause the pancreas to exocytose insulin into the bloodstream.
Scientists speculate the action of Liraglutide may be magnified if given in conjunction with a certain set of other compounds. In a trial completed in 2007, the Liraglutide peptide was introduced into the pancreas of rats that already had sulfonylurea molecules. The research findings suggested that "GLP-1to be isolated perfused rat pancreases at low perfusate glucose concentrations do not affect insulin secretion" but that "sulfonylurea pretreatment resulted in dramatic stimulation of insulin secretion. "The results demonstrated that when given sulfonylurea and a GLP-1 agonist, 30 to 40 percent of subjects suffered from hypoglycemia." [ii]
Liraglutide Research And Clinical Investigations
Based on the outcomes of research carried out in 2006, it has been hypothesized that GLP-1 may prevent the destruction of islet cells and the death of pancreatic beta cells. [iii]
Research results imply that Liraglutide may cause satiety and a reduction in food consumption. Recent clinical investigations suggest that when mice were given Liraglutide peptide twice daily, it seemed to promote progressive, linear weight reduction and decreased hunger. These results were seen in mice. [iv] Liraglutide may assist in decreasing the risk of issues linked with high blood sugar and insulin by potentially assisting in reducing excessive body weight.
It is believed that GLP-1 agonistic receptors may be found throughout the heart muscle. The peptide known as Liraglutide has been hypothesized to modulate cardiac function, increase heart rate, and lower blood pressure. It has been proposed that Liraglutide may work via binding, stimulating glucose absorption inside the cardiac muscles. Studies suggest this may possibly allow oxygen-derived (ischemic) heart muscles to absorb glucose through Liraglutide. GLP-1 was proposed for the first time by A.K. Bose and colleagues, who stated that " The discovery that GLP-1 and its analogs may have protective effects on the heart suggests these substances could offer new therapeutic potential. Their benefit seems to stem from the activation of multiple prosurvival kinases." [v]
Researchers suggest the peptide may bind with certain receptors in the brain, which may improve mice's "associative learning" and "spatial learning" capabilities. According to Matthew J. During, "The GLP-1 receptor exhibits tremendous capacity as an emerging focus for creating treatments that boost brain function and safeguard neurons." [vi]
Peptides may only be purchased by academic and scientific institutions, not individuals or companies. If you are a licensed professional interested in purchasing Liraglutide peptides for your clinical studies, visit Biotech Peptides. Please note that the substances discussed here are intended only for in vitro and in-lab research purposes. They are not approved for consumption by humans or animals. Any physical administration is prohibited. Purchases are restricted to authorized academics and professionals. The content here is intended solely for educational purposes.
References
[i] National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 16134956, Liraglutide. Retrieved November 14, 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/Liraglutide
[ii] Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. DOI: 10.1152/physrev.00034.2006. PMID: 17928588. https://pubmed.ncbi.nlm.nih.gov/17928588/
[iii] Tandong Yang, Meng Chen, Jeffrey D. Carter, Craig S. Nunemaker, James C. Garmey, Sarah D. Kimble, Jerry L. Nadler, Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes, Biochemical and Biophysical Research Communications, Volume 344, Issue 3, 2006, Pages 1017-1022, ISSN 0006-291X, https://www.sciencedirect.com/science/article/pii/S0006291X06007066
[iv] Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/16776751/
[v] Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005. https://pubmed.ncbi.nlm.nih.gov/15616022/
[vi] During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003 Sep; https://pubmed.ncbi.nlm.nih.gov/12925848
Note- This article is written by Brand Desk.
